祛痰利肺汤治疗慢性阻塞性肺疾病急性加重期(痰浊壅肺)咳喘的疗效及对血清炎性因子的影响

Efficacy of Qutan Lifei Decoction in the treatment of cough and asthma in patients with acute exacerbation of chronic obstructive pulmonary disease(phlegm-dampness retention in lungs)and its influence on serum inflammatory factors

目的观察祛痰利肺汤治疗慢性阻塞性肺疾病急性加重期(AECOPD)(痰浊壅肺)咳喘的疗效及对血清炎性因子的影响。方法回顾性分析55例AECOPD(痰浊壅肺)咳喘患者临床资料,根据患者实施的治疗方式不同分为对照组(15例)和研究组(40例)。对照组采用常规西药治疗,研究组在对照组治疗基础上联合祛痰利肺汤加减治疗。比较两组患者治疗前后血清炎性因子[白细胞计数(WBC)、同型半胱氨酸(Hcy)、C反应蛋白(CRP)、降钙素原(PCT)]、肺功能指标[肺活量占预计值的百分比(VC%)、用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC]水平以及临床疗效。结果治疗后,两组患者WBC、CRP、PCT、Hcy水平均低于本组治疗前,且研究组患者WBC(7.56±0.75)×10^(9)/L、CRP(15.27±1.01)mg/L、PCT(0.63±0.22)ng/ml、Hcy(18.21±0.63)μmol/L均低于对照组的(8.98±1.24)×10^(9)/L、(18.54±1.11)mg/L、(1.18±0.45)ng/ml、(29.72±0.96)μmol/L,差异均具有统计学意义(P<0.05)。治疗后,两组患者FEV1、FVC、VC%、FEV1/FVC均高于本组治疗前,且研究组患者FEV1(2.31±0.28)L、FVC(3.15±0.26)L、VC%(83.46±6.10)%、FEV1/FVC(76.37±3.85)%高于对照组的(2.00±0.22)L、(2.79±0.10)L、(78.84±8.03)%、(70.81±4.59)%,差异具有统计学意义(P<0.05)。研究组治疗总有效率97.50%高于对照组的73.33%,差异具有统计学意义(P<0.05)。结论AECOPD(痰浊壅肺)咳喘患者实施祛痰利肺汤治疗,可明显降低患者血清炎性因子水平,提升临床治疗效果。

Objective To observe the efficacy of Qutan Lifei Decoction in the treatment of cough and asthma in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)(phlegmdampness retention in lungs)and its influence on serum inflammatory factors.Methods A total of 55 AECOPD(phlegm-dampness retention in lungs)patients with cough and asthma were divided into control group(15 cases)and research group(40 cases)according to the different treatment methods.The control group was treated with conventional western medicine,and the research group was treated with Qutan Lifei Decoction on the basis of the treatment of the control group.Both groups were compared in terms of serum inflammatory factors[white blood cell count(WBC),homocysteine(Hcy),C-reactive protein(CRP),procalcitonin(PCT)],pulmonary function indexes[percentage of vital capacity as a percentage of the predicted value(VC%),forced vital capacity(FVC),forced expiratory volume in the 1st second(FEV1),FEV1/FVC]levels and clinical efficacy.Results After treatment,the levels of WBC,CRP,PCT and Hcy in the two groups were lower than those before treatment in this group,and the WBC(7.56±0.75)×10^(9)/L,CRP(15.27±1.01)mg/L,PCT(0.63±0.22)ng/ml,Hcy(18.21±0.63)μmol/L in the research group were lower than(8.98±1.24)×10^(9)/L,(18.54±1.11)mg/L,(1.18±0.45)ng/ml,(29.72±0.96)μmol/L in the control group.All the differences were statistically significant(P<0.05).After treatment,the FEV1,FVC,VC%,and FEV1/FVC in the two groups were higher than those before treatment in this group,and the FEV1(2.31±0.28)L,FVC(3.15±0.26)L,and VC%(83.46±6.10)%,FEV1/FVC(76.37±3.85)%in the research group were higher than(2.00±0.22)L,(2.79±0.10)L,(78.84±8.03)%,(70.81±4.59)%in the control group.All the differences were statistically significant(P<0.05).The total effective rate 97.50%of the research group was higher than 73.33%of the control group,and the difference was statistically significant(P<0.05).Conclusion Qutan Lifei Decoction can obviously lower the serum inflammatory factors of AECOPD(phlegm-dampness retention in lungs)patients with cough and asthma,and improve their clinical effect.